Moore Capital Management, LP Blueprint Medicines Corp Transaction History

Moore Capital Management, LP

  • $4.85 Billion
  • Q3 2024

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$49.93 - $77.7 $11.3 Million - $17.6 Million
226,782 New
226,782 $14.9 Million
Q1 2022

May 16, 2022
SELL
$54.1 - $110.08 $2.09 Million - $4.26 Million
-38,654 Closed
0 $0
Q4 2021

Feb 14, 2022
SELL
$94.25 - $115.99 $11.9 Million - $14.7 Million
-126,415 Reduced 76.58%
38,654 $4.14 Million
Q3 2021

Nov 15, 2021
SELL
$80.98 - $109.47 $2.36 Million - $3.19 Million
-29,114 Reduced 14.99%
165,069 $17 Million
Q2 2021

Aug 16, 2021
BUY
$82.78 - $101.0 $6.4 Million - $7.8 Million
77,272 Added 66.09%
194,183 $17.1 Million
Q1 2021

May 17, 2021
SELL
$90.71 - $108.28 $8.03 Million - $9.59 Million
-88,543 Reduced 43.1%
116,911 $11.4 Million
Q4 2020

Feb 16, 2021
BUY
$92.08 - $124.48 $7.9 Million - $10.7 Million
85,802 Added 71.71%
205,454 $23 Million
Q3 2020

Nov 16, 2020
BUY
$66.45 - $92.7 $6.29 Million - $8.77 Million
94,652 Added 378.61%
119,652 $11.1 Million
Q2 2020

Aug 14, 2020
BUY
$57.09 - $79.27 $1.43 Million - $1.98 Million
25,000 New
25,000 $1.95 Million
Q1 2018

May 15, 2018
SELL
$73.28 - $102.95 $2.56 Million - $3.6 Million
-35,000 Closed
0 $0
Q4 2017

Feb 14, 2018
BUY
$62.91 - $88.32 $2.2 Million - $3.09 Million
35,000
35,000 $2.64 Million

Others Institutions Holding BPMC

# of Institutions
351
Shares Held
60.3M
Call Options Held
2.25M
Put Options Held
1.18M
View Full List

About Blueprint Medicines Corp

BPMC Quotes by TradingView
  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Moore Capital Management, LP Portfolio

Follow Moore Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Moore Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email